Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
15 participants
INTERVENTIONAL
2008-06-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223
Tissue Collection From People With Cystic Fibrosis
NCT00015756
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
NCT00043316
Ketone Supplementation in Cystic Fibrosis
NCT04938726
Statins To Treat Adult Cystic Fibrosis
NCT01092572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IGF-1
Recombinant human IGF-1
recombinant human IGF-1
rhIGF-1
Placebo
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
recombinant human IGF-1
rhIGF-1
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 yr.
* Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5
Exclusion Criteria
* Diabetic retinopathy
* Obstructive sleep apnea
* Respiratory failure requiring mechanical ventilation.
* Status post pulmonary transplantation.
* Concurrent or recent (within past 6 months) receipt of human growth hormone.
* History of adverse side effects to growth hormone other than carbohydrate intolerance.
* Pregnancy or attempting pregnancy.
* Women who are breast feeding.
* Sexually active women who refuse to use or are incapable of responsibly using reliable contraception.
* Proven non compliance with medical regimens.
* Inability or refusal to take subcutaneous injections.
* Known allergy to components in the IGF-I preparation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stony Brook University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas A. Wilson
Professor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas A Wilson, MD
Role: PRINCIPAL_INVESTIGATOR
State Univeristy of New York, Stony Brook, NY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
State University of New York
Stony Brook, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IGF-1 in Cystic Fibrosis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.